What is the share price of Ankur Drugs & Pharma Ltd (ANKURDRUGS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Ankur Drugs & Pharma Ltd (ANKURDRUGS) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Ankur Drugs & Pharma?

The latest standalone P/E ratio of Ankur Drugs & Pharma as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Ankur Drugs & Pharma Ltd (ANKURDRUGS)?

The latest standalone P/B ratio of Ankur Drugs & Pharma Ltd (ANKURDRUGS) as of 01-Jan-1970 is -0.04.

What is the 52-week high and low of Ankur Drugs & Pharma Ltd (ANKURDRUGS)?

The 52-week high of Ankur Drugs & Pharma Ltd (ANKURDRUGS) is Rs. 4.02 and the 52-week low is Rs. 3.65.

Ankur Drugs & Pharma Ltd (ANKURDRUGS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Ankur Drugs & Pharma Ltd (ANKURDRUGS)
Brand: Ankur Drugs & Pharma

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531683 NSE: ANKURDRUGS Pharmaceuticals & Drugs | Small Cap | Ankur Drugs & Pharma Share Price

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531683 NSE: ANKURDRUGS Pharmaceuticals & Drugs | Small Cap | Ankur Drugs & Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹8 Cr.

Current Price

₹0

52-Week Low / High

₹4 / 4

TTM EPS

₹-127.9

TTM Sales

₹142 Cr.

Book Value per Share

₹-95.9

P/E Ratio

0.00

Industry PE

46.6

Price to Book (P/B)

-0.04

Price to Sales (P/S)

0.05

EV/EBITDA

-16.77

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

-328.47%

Return on Capital Employed (ROCE)

-16.03%

Return on Assets (ROA)

-18.59%

Operating Profit Margin

-16.4%

Net Profit Margin

-202.98%

Gross Profit Margin

-59.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-81.63%

Operating Profit Growth (1 Year)

-124.45%

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

5.90%

Pledged shares (%) of Promoter's holding (%)

14.99%

Reserves

₹-166 Cr.

Equity

₹19.3 Cr.

Face Value

₹10

All Time Low / High

₹1.75 / 486.90

Ankur Drugs & Pharma stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
ROCE % ⓘ	10.7%	26.3%	21.7%	19.2%	17.4%	15.4%	12.2%	17.6%	5.4%	-16%	-
Growth Parameters ⓘ
Sales ⓘ	18.3	54.9	78.6	136	373	674	965	1,067	825	151	142
Sales YoY Gr.	-	200.5%	43.1%	73.6%	173.5%	80.5%	43.3%	10.6%	-22.7%	-81.6%	-
Adj EPS ⓘ	0.9	4	5.2	14.7	31	50	30.3	38.6	-35.1	-106.8	-127.9
YoY Gr.	-	325.5%	30.8%	181.6%	110.5%	61.2%	-39.4%	27.3%	-191.1%	NA	-
BVPS (₹) ⓘ	10.8	12.9	17	30.1	99.2	165.5	140.4	164	126.6	-29.8	-95.9
Adj Net Profit ⓘ	0.9	3.8	5	14	32.7	63.5	56.4	74.6	-67.9	-206	-247
Cash Flow from Ops. ⓘ	-1	3.4	5	7.6	22.9	21.5	41.9	844	-40.5	3.2	-
Debt/CF from Ops. ⓘ	-14.9	7.9	9.5	14.7	15.4	28.8	17.8	1.1	-30.1	309	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.5%	-16.5%	-46.1%	-81.6%
Adj EPS ⓘ	-269.2%	-228.1%	-252.2%	NA
BVPSⓘ	-212%	-178.6%	-159.7%	-123.6%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
Return on Equity % ⓘ	8.7	32.6	34.1	61.8	46.1	38.2	23	23.7	-21	-78.4	203.4
Op. Profit Mgn % ⓘ	18.2	18.4	16.7	16.1	15.5	15.9	16.4	19.6	16.4	-16.4	-25.2
Net Profit Mgn % ⓘ	4.7	6.9	6.3	10.3	8.8	9.4	5.8	7	-8.2	-136.3	-173.6
Debt to Equity ⓘ	1.5	2.2	3	3.9	3.4	2.9	2.9	3	5	-17.1	-
Working Cap Days ⓘ	93	85	108	107	97	120	151	142	124	348	109
Cash Conv. Cycle ⓘ	50	60	87	89	76	98	128	32	-34	102	-421

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Sales	18.28	54.93	78.58	136.45	373.24	673.50	965.32	1,067.41	824.85	151.49
Operating Expenses ⓘ +	14.94	44.81	65.44	114.53	315.27	566.65	834.57	858.65	690.95	184.23
Manufacturing Costs	2.86	9.28	13.91	26.79	66.02	111.60	120.62	125.83	37.90	27.87
Material Costs	10.37	34.33	49.26	84.92	245.70	448.51	641.12	697.61	616.42	113.19
Employee Cost	0.94	0.22	0.23	0.23	0.59	1.36	12.24	15.80	20.44	18.80
Other Costs ⓘ	0.77	0.98	2.04	2.59	2.96	5.18	60.59	19.42	16.19	24.37
Operating Profit ⓘ	3.33	10.12	13.14	21.92	57.97	106.85	130.75	208.76	133.90	-32.74
Operating Profit Margin (%)	18.2%	18.4%	16.7%	16.1%	15.5%	15.9%	13.5%	19.6%	16.2%	-21.6%
Other Income ⓘ +	0.01	0.28	0.04	0.14	0.49	1.51	2.94	18.63	0.93	17.54
Exceptional Items ⓘ	0	-1	0	0	0	0	0	0	0	-136.37
Interest ⓘ	0.79	2.03	3.92	4.08	12.92	24.93	54.10	80.75	120.80	75.71
Depreciation ⓘ	0.96	1.04	2.02	2.50	6.02	8.40	20.67	26.64	60.80	61.19
Profit Before Tax ⓘ	1.59	6.33	7.24	15.48	39.52	75.02	58.92	120	-46.77	-288.47
Tax ⓘ	0.73	3.23	2.27	1.51	6.79	11.51	21.79	33.82	22.04	19.02
Profit After Tax	0.86	3.10	4.97	13.98	32.73	63.50	37.13	86.18	-68.81	-307.49
PAT Margin (%)	4.7%	5.6%	6.3%	10.3%	8.8%	9.4%	3.9%	8.1%	-8.3%	-203.0%
Adjusted EPS (₹)	0.9	3.3	5.2	14.7	31.0	50.0	19.9	44.6	-35.6	-159.0
Dividend Payout Ratio (%)	0%	30.70%	19.10%	10.20%	6.50%	4.50%	11.30%	5.10%	0%	0%

Valuation of Ankur Drugs & Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Equity and Liabilities
Shareholders Fund +	10.21	12.64	16.46	28.82	105.08	210.74	261.63	357.28	288.47	-19.02
Share Capital ⓘ	9.08	9.50	9.50	9.50	10.56	12.70	18.62	19.34	19.34	19.34
Reserves ⓘ	1.12	3.14	6.96	19.32	94.53	198.04	243.01	337.94	269.13	-38.36
Debt +	14.31	26.78	47.80	111.32	351.79	618.14	744.70	950.41	980.38	712.12
Long Term Debt	14.31	26.78	47.80	111.32	351.79	618.14	744.70	950.41	458.96	598.28
Short Term Debt	0	0	0	0	0	0	0	0	521.42	113.84
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1.78	3.53	2.27	5.41	25.25	27.15	57.42	450.72	131.86	136.56
Others Liabilities ⓘ	1.28	5.37	7.80	10.92	23.06	43.89	70.79	114.95	378.77	698.99
Total Liabilities ⓘ	27.58	48.32	74.33	156.47	505.18	899.92	1,134.53	1,873.37	1,779.48	1,528.65
Fixed Assets
Net Fixed Assets ⓘ +	18.82	20.92	33.12	32.99	112.38	204.16	346.15	704.41	1,219.86	1,158.69
Gross Block	21.42	24.55	38.77	41.14	127.96	228.04	390.65	775.47	1,351.40	1,351.26
Accumulated Depreciation	2.59	3.63	5.66	8.16	15.58	23.89	44.50	71.07	131.54	192.57
CWIP ⓘ	0	6.46	8.68	65.61	245.03	331.49	266.10	785.88	284.97	266.48
Investments ⓘ	0	0.01	0.01	0.01	0.02	5.24	3.74	0.36	0.10	0.10
Inventories	3.71	11.10	14.48	24.56	62.18	123.15	212.77	260.85	165.36	17.69
Trade Receivables	4.27	8.40	15.31	28.35	76.90	163.91	281.14	54.85	38.17	31.76
Cash Equivalents	0.11	0.40	0.75	1.74	2.56	59.06	15.84	9.43	3.07	2.16
Others Assets ⓘ	0.65	1.04	1.98	3.21	6.11	12.92	8.79	57.59	67.96	51.78
Total Assets ⓘ	27.58	48.32	74.33	156.47	505.18	899.92	1,134.53	1,873.37	1,779.48	1,528.65

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Cash Flow From Operating Activity ⓘ +	-0.96	3.38	5.01	7.57	22.86	21.50	41.87	843.72	-40.54	3.20
PBT ⓘ	1.61	7.30	7.28	15.41	39.36	75	58.92	120	-46.77	-288.47
Adjustment ⓘ	0.99	2.90	5.92	6.68	18.82	32.09	120.58	92.51	181.92	268.52
Changes in Working Capital ⓘ	-3.56	-3.8	-3.65	-9.72	-19.38	-51.28	-78	731.27	-170.65	24.46
Tax Paid ⓘ	0	0	-0.62	-0.72	-3.02	-9.38	-5.53	-19.31	-5.04	-1.30
Cash Flow From Investing Activity ⓘ +	-0.96	-9.34	-16.40	-59.28	-187.75	-190.75	-94.27	-938.33	-91.53	23.96
Capex	-1.06	-3.13	-16.44	-59.34	-188.04	-186.53	-97.25	-904.75	-76.72	8.13
Net Investments	0.10	-0.01	0	0	-0.01	-5.22	0.08	4.74	0.28	0
Others ⓘ	0.01	-6.21	0.04	0.06	0.30	1	2.91	-38.32	-15.09	15.84
Cash Flow From Financing Activity ⓘ +	1.98	6.26	11.74	52.69	165.17	225.75	9.18	88.21	130.15	-26.92
Net Proceeds from Shares ⓘ	0.76	0	0	0	18.36	47.81	20.07	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	-109.83	-16.54
Dividend Paid ⓘ	0	0	-0.95	-0.95	-1.43	-2.54	-4.19	-4.28	-4.35	0
Others ⓘ	1.22	6.26	12.69	53.64	148.23	180.48	-6.70	92.49	244.32	-10.38
Net Cash Flow ⓘ	0.07	0.29	0.35	0.99	0.27	56.50	-43.22	-6.41	-1.92	0.25

Financial Ratio

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Ratios
ROE (%)	9.38	28.07	34.93	62.51	49.12	40.33	15.75	29.79	-24.48	N/A
ROCE (%)	10.71	26.3	21.67	19.2	17.35	15.36	12.2	17.58	5.42	N/A
Asset Turnover Ratio	0.84	1.61	1.43	1.29	1.14	0.96	0.95	0.71	0.45	0.09
PAT to CFO Conversion(x)	-1.12	1.09	1.01	0.54	0.7	0.34	1.13	9.79	N/A	N/A
Working Capital Days
Receivable Days	43	37.80	49.50	53.50	51	65.10	83.80	57.30	20.50	83.80
Inventory Days	40.20	44.10	53.40	47.80	42.10	50.10	63.30	80.70	93.90	219.20
Payable Days	48.70	28.30	21.50	16.50	22.80	21.30	24.10	132.90	172.50	432.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

59.41

79.60

76.77

72.58

71.65

69.92

57.87

47.63

12.36

14.99

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Ankur Drugs & Pharma Ltd FAQs

The current trading price of Ankur Drugs & Pharma on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Ankur Drugs & Pharma stood at ₹7.60 Cr

The latest P/E ratio of Ankur Drugs & Pharma as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Ankur Drugs & Pharma as of 31-Dec-1969 is -0.04.

The 52-week high of Ankur Drugs & Pharma is ₹4.02 and the 52-week low is ₹3.65.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ankur Drugs & Pharma is ₹142 ( Cr.) .

Data is not available for this company.

No data found

About Ankur Drugs & Pharma Ltd

Ankur Drugs and Pharma, formerly the Mridol Pharmaceuticals Limited was incorporated on February 9, 1995 with the Registrar of Companies, Maharashtra at Mumbai and a certificate of commencement of business was obtained on 7 March 1995. The Company was promoted by Shri Sandeep Parwal and Shri Harinarayan Attal. The company came up with a Public Issue of 57,00,000 Equity shares of Rs.10 each for cash at par opened for subscription in 1996 and the issue was oversubscribed.

The name of the company was changed from Mridol Pharmaceuticals Limited to Ankur Drugs and Pharma Limited in 1998.

Currently Ankur manufactures 400 different formulations for different dosage forms - viz Tablets, Capsules, Dry syrups, Liquid Orals,etc. Right from inception, Ankur has remained focused on its core business of Contract manufacturing. Since the last six years the company has not diluted itâ€™s equity base. Ankur's debt level appears high primarily because of â€œExpansion for Growthâ€. Ankur has used its debts mostly to fund the core business expansion at Baddi by creating production facility for â€œbest in worldâ€. Currently company operates in the ratio of 40% Loan License and 60% Third Party which it proposes to be 50:50 in coming future. Looking at the current business model companyâ€™s basic strategy is to approach big domestic players for contract manufacturing in formulations and maintain a sustainable net margin of 10% in their overall business. The company is targeting to grow multifold in coming years through contract manufacturing.

The company has recently announced that it will invest in the entire paid up share capital of TVC Life Sciences Ltd. in order to make it its wholly owned subsidiary. The group is engaged in manufacturing of pharma formulation in various dosage forms for leading Indian Companies. It is into 100% Contract Manufacturing activity and the plants are strategically located offering varied financial advantages to its customers.

Products:

ADPL is currently manufacturing brands like Mox, Cifran, Sporidex, Romilast, Fenak Plus, Omesec-20, Stanhist, Secafe, etc

Clientele:

Ranbaxy Laboratories Limited
Cipla Limited
Khandelwal Laboratories Pvt. Limited
Makers Laboratories Limited
Hetero Healthcare Limited
Elder Pharma Limited
Lyka Labs Limited
Blue Cross Laboratories Limited
Cadila Laboratories Limited
Wockhardt Limited
Glenmark Pharma Limited
Parentral Drugs (India) Limited
Torrent Pharmaceuticals Limited
Sandoz (India) pvt Limited
Shreya Life Sicences Pvt. Limited
Synthiko Formulations
Nicholas Piramal India Limited

The company is planning for various international approvals mainly the US FDA and EU MHRA for the Baddi Plant which would help the company to start export business.

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Ankur Drugs & Pharma stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Ankur Drugs & Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Ankur Drugs & Pharma Ltd FAQs

About Ankur Drugs & Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Ankur Drugs & Pharma Ltd (ANKURDRUGS)

Ankur Drugs & Pharma stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Ankur Drugs & Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Ankur Drugs & Pharma Ltd FAQs

What is the share price of Ankur Drugs & Pharma?

What is the market cap of Ankur Drugs & Pharma?

What is the P/E ratio of Ankur Drugs & Pharma?

What is the P/B ratio of Ankur Drugs & Pharma?

What is the 52-week high and low of Ankur Drugs & Pharma?

What is the TTM revenue of Ankur Drugs & Pharma?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Ankur Drugs & Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.